A real world cost effectiveness analysis of interferon-based therapy for HCV naïve super-responders.

摘要: Abstract Background A direct-acting antiviral (DAA) era in hepatitis C virus (HCV) treatment is fast approaching; unfortunately, the availability and affordability of DAAs Asia–Pacific areas vary, making it difficult to develop universal HCV practice guidelines appropriate for all Asian populations. This study aimed evaluate real-world cost-effectiveness IFN-based therapy according current strategies with PegIFN/RBV “easy-to-treat” provide a reference application future DAA development IFN-eligible, naive patients. Methods total 1032 chronic treatment-naive patients who corresponded response-guided (RGT) regimens were linked entire population expenditures order National Health Insurance Research Database Taiwan. The average cost per SVR achieved was calculated as summation treated patients/number cases. Results Current RGT suggested 24 weeks G1 baseline LVL RVR at week 4 an $5090 ± 2400. superior compared those other subgroups In terms G2 patients, 16 duration, very competitive ($3237 ± 488). Conclusion For patient new era, might be conserved favorable risk parameters, considering duration SVR, resource-constrained countries.